Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

(2011) L. V. Sequist et al.   ANNALS OF ONCOLOGY

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

(2011) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

(2011) Antonio Marchetti et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations

(2011) Paul K. Paik et al.   JOURNAL OF CLINICAL ONCOLOGY

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer

(2011) Zengliu Su et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

(2011) Kenichi Suda et al.   Journal of Thoracic Oncology

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma-Rationale for Comprehensive Mutation Profiling

(2011) J. E. Chaft et al.   MOLECULAR CANCER THERAPEUTICS

Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling

(2011) J. Chmielecki et al.   Science Translational Medicine

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

(2010) K. Suda et al.   CLINICAL CANCER RESEARCH

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

(2010) Dora Dias-Santagata et al.   EMBO Molecular Medicine

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo

(2009) E. Ichihara et al.   CANCER RESEARCH

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

(2009) K. Politi et al.   Disease Models & Mechanisms

Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma

(2008) J. L. Marks et al.   CANCER RESEARCH

PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

(2008) H. Yamamoto et al.   CANCER RESEARCH

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors

(2008) Narasimhan P. Agaram et al.   GENES CHROMOSOMES & CANCER

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE